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This dissertation includes a comprehensive current review of reversible electroporation 
(EP) and other related physical gene transfection techniques; an overview of results of 
electrochemogene therapy (ECGT) used to treat naturally occurring spontaneous neoplasms in 
dogs; and the results of comprehensive, pre-clinical toxicology testing of electrogene therapy 
(EGT) of a tumor-targeted version of interleukin-12 (IL-12) in mice.    
 Intralesional bleomycin (BLM) and feline interleukin-12 (fIL-12) DNA injection 
combined with trans-lesional EP resulted in complete cure of two recurrent oral squamous cell 
carcinomas and an acanthomatous ameloblastoma in a series of six cases of spontaneous 
neoplasia in pet dogs.  The three remaining dogs, which had no other treatment options, had 
partial responses to ECGT.  One of these dogs had mandibular melanoma with pulmonary and 
lymph node metastases; one dog had cubital histiocytic sarcoma with spleen metastases; and one 
had soft palate fibrosarcoma.  Treatment of all six dogs was associated with minimal side effects, 
was easy to perform, was associated with repair of bone lysis in cured dogs; improved the quality 
of life for dogs with partial responses; and extended overall survival time.  
For the purpose of meeting pre-clinical safety requirements for an Investigational New 
Drug filing, we assessed the safety of tumor-targeted interleukin-12 (ttIL-12) when administered 
by EGT in C3H/HeJ mice by identifying an initial safe dose for human dose escalation schemes, 
toxicity target organs, markers of toxicity, and toxicity reversibility.  Dystrophic cardiac 
calcification in older, 5 µg ttIL-12-treated mice was the only serious toxicity.  Based on these 
results and the lack of any effect on wound healing when combined with surgery, low-intensity 
EGT with ttIL-12 appears to be safe and well tolerated as both a single treatment modality and 






















































 Although there have been tremendous advances in cancer treatment over the past few 
decades, it still remains a major killer; in 2007, the cancer mortality rate was second only to heart 
disease.  In other words, cancer represented roughly a quarter of all deaths in the United States or 
562,875 people1.  The majority of these deaths continue to be a result of recurrent or metastatic 
disease; therefore treatments addressing prevention or treatment of cancer recurrence and 
metastasis are essential for making a significant impact in the war against cancer.  
 Surgery remains the primary treatment modality for many solid tumors and is often 
combined with or supplanted by radiation and/or chemotherapy.  In some cases surgery alone 
may result in a clinical cure, but many times either the location of the tumor or pre-existing 
micrometastases preclude complete cure.  Despite lack of clinical cure, one of the benefits of 
surgical removal of the primary tumor is that the majority of metastatic tumor cells enter into a 
growth phase either because of lack of growth factor inhibition by the primary tumor or because 
of inflammatory effects of the surgery.  Entry into the growth phase is essential for efficacy of 
radiation or chemotherapy.  Other small molecule inhibitors and monoclonal antibodies also 
perform best in the setting of cell proliferation.  Cancer immunotherapy is somewhat unique in 
that it usually does not require actively proliferating cells, instead relying on tumor specific 
antigens or lack of MHC expression to recognize and kill tumor cells through the 
immunosurveillance activities of the immune system.  This becomes even more important with 
the knowledge that many tumors have a small quiescent population of tumor stem cells which 
drive tumor recurrence and may be important in tumor metastasis.  Targeting this population of 
tumor cells may be the key to curing many cancers.  
 Cancer immunotherapy has been used for a variety of tumors for several years now.  
Immunotherapeutic strategies include recombinant cytokine therapy, dendritic cell manipulation 
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through either ex vivo manipulation and re-introduction to other in vivo modifications, and use 
of a variety of non-specific immunostimulants.  Although recombinant cytokine therapy has had 
a number of safety issues, cytokine gene therapy avoids these problems by targeting tumors 
allowing safe sustained (for a limited period of time) systemic levels of circulating cytokines.  
Our laboratory has been actively developing a number of these gene therapies, the most 
promising of which is Interleukin-12 (IL-12) electrogene therapy.   We have also looked at co-
stimulatory molecule gene therapy and a number of other cytokine genes, but at this point IL-12 
appears to offer the most promise.  We have found this therapy to be efficacious in mice and to 
be both safe and effective when combined with bleomycin electrochemotherapy or surgery in 
both mice and dogs. 
Given that our chosen means of gene transfection is by electroporation, chapter two 
covers recent advances in large animal electroporation therapy.2  In chapter three, examples of 
clinical use of combination chemotherapy and cytokine gene therapy mediated by 
electroporation is discussed with demonstration of safety and efficacy in dogs with a variety of 
neoplasms.3  In chapter four, controlled experimental pre-clinical safety studies provide firm 
evidence of the safety of this treatment prior to escalation to human clinical trials.4  Finally, 
chapter five summarizes our findings and suggests further directions for this work along with 
potential applications. 
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 Gene therapy has become an important potential treatment modality for a variety of 
disorders and has shown great promise for treating genetic deficiencies and mutations, as well as 
for providing secreted therapeutic proteins and immune modulators.  Gene therapy has also 
become important in preventing disease by use of DNA vaccines.  Furthermore, in production 
animals, gene therapy has been used to enhance reproductive efficiency and production gains.   
 A variety of means for introducing genes into mammalian cells have been used that can 
be broadly categorized as viral, chemical, and physical methods.  There is a general consensus 
that viral vectors are the most efficient means of gene transfection, but significant safety 
concerns, such as the potential to illicit an immune response and/or cause cellular transformation 
limit virus use in a variety of settings.   Chemical methods can be effective in vitro, but their use 
in vivo needs further improvement because their transfection efficiency is lower than for viral 
and physical methods in most of cases.  Physical transfection avoids many of the undesirable 
effects of chemical and viral methods, can be used repetitively, is relatively simple and cost-
effective, and has essential no limitation on the coding length of the gene to be introduced.  Of 
the physical methods of gene transfection, electroporation (EP) is the most commonly used 
method in a variety of animal and human trials.     
Historically, gene therapy in large animals (defined as species of animals other than rats, 
mice, and small rodents) has been pursued using viral and non-viral vectors carrying genes to be 
transfected into host cells.  Since in vivo EP has emerged as one of the few powerful non-viral 
vector delivery methods for efficiently and effectively delivering plasmid DNA and nucleic acids 
in vivo, this review will be limited to EP-based gene therapy.  For the purpose of this review, in 
vivo EP refers to reversible EP for the purpose of gene delivery, not irreversible EP where the 
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therapeutic intent is ablation of cells using EP technique alone.  Several recent reviews 
examining the use of irreversible 5-11 and reversible 12-15 EP are published elsewhere.  The 
focuses of this review are novel aspects of EP as applied to large animals, improvement of EP 
delivery technique, and development of EP-based vaccines. 
THE MECHANISM FOR EP-MEDIATED DNA ENTRY INTO CELLS  
During EP, a series of square-wave electric pulses are used to drive naked DNA into 
cells.  A stable, non-dividing population of muscle cells is transfected when long-term 
expression of a gene is desired, for example in supplementing clotting factors to treat hemophilia 
(though immunogenicity often neutralizes the circulated clotting factor).16, 17   Alternatively, a 
tumor’s population of neoplastic cells, stromal cells, and attending inflammatory cells are 
transfected in tumor gene therapy, for example introducing interleukin 12 to trigger anti-tumor 
immunity.18   Regardless of the target cells transfected, EP exposes tissue to a brief electric field 
which induces temporary and reversible breakdown of cell membranes and formation of pores.  
The electric field also takes advantage of the tendency of negatively-charged nucleic acid to 
migrate toward the positive pole in an electric field (an electrophoretic effect).    
Within the cell membrane, pores form within 10 ns 19 and initially are less than 10 nm in 
diameter. 20, 21  While the duration of pore formation may be short, reconstitution of the cell 
membrane may be prolonged by decreasing temperature.  However with longer duration electric 
field application, pore number increases and pores begin to coalesce.  When large enough pores 
form, the damage becomes irreversible and cells die (irreversible EP).  Fortunately, the size of 
pores normally is not a limiting factor, both small oligonucleotides and nucleotides larger than 
150 kb, which is larger than the pores, have been shown to readily enter the cell during EP.  This 
fact suggests that the mechanism of gene transfer into cells may simply be based on diffusion;22 
or, as other researchers have suggested, that electric-pulse-induced membrane instability causes 
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membrane bound vesicles containing DNA to form which are carried into the cell by 
endocytosis.23  Despite numerous theories, the mechanism of nucleic acid entry into cells remains 
open to conjecture.24  All models explaining nucleotide migration through the cell membrane 
must be based on several physical postulates including:  the existence of long-lived 
electropores,25-27 a preliminary binding step at the cell surface due to membrane plasmid DNA 
interaction and then DNA diffusion through electropores,26 electrophoretic forces generated by 
the external field which push the plasmid DNA through the membrane.28, 29  Interactions have 
been observed between DNA and model lipid bilayers which suggest that other mechanisms, 
including endocytosis, may also play a role in membrane-DNA interaction.  In fact, DNA-
induced endocytosis has been observed in a number of studies, in the absence of any electric 
field.30, 31   
It is generally accepted that when the cell membrane is not permeabilized, electric field 
lines or vectors follow the outer profile of the cell, and DNA flows in the direction of the field 
around the cell to the anode.  When the membrane is permeabilized, electric field lines enter the 
cell membrane and DNA is trapped in the region of the cell membrane opposite the cathode 
where it is effectively pushed up against the membrane by electrophoretic force.24  Interaction 
with the permeabilized membrane prevents DNA from flowing around the cell.  Thus, Favard, et 
al., conclude that electrotransfection is a multistep process where negatively charged DNA 
migrates by electrophoresis towards the cell plasma membrane on the cathode side where it 
accumulates.24  When electric fields exceed a certain threshold, the plasma membrane is 
permeabilized allowing accumulated plasmid DNA to enter.  This translocation of plasmid DNA 
from the plasma membrane to the cytosol and subsequent passage to the nuclear envelope takes 
minutes to hours.  Intracellular movement also occurs by an as yet undetermined mechanism 
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which may involve simple diffusion, endocytosis, or electrophoretic movement.   Upon entering 
the nucleus, gene transcription from plasmid DNA can take place.24  
ACHIEVING HIGH-LEVEL AND LONG-TERM GENE EXPRESSION 
In most cases, the DNA that enters the nucleus is transiently transcribed and rarely 
integrated into the host cell genome.  Although this means that the frequency of genome 
disruption is lower than techniques involving integration of the gene in the host genome,32 the 
optimal conditions for long-term levels of transgene expression without adverse side effects, 
remains a primary objective for researchers.33  Despite the fact that transient expression of the 
transgene remains one of the major shortcomings of nonviral DNA delivery, this shortcoming 
can partially be alleviated by using post-mitotic, stable cells, such as myocytes.  EP-mediated 
gene therapy in continually dividing cells often yields declining transgene expression, probably 
due to degradation, since extrachromosomal DNA is known to persist in post-mitotic tissues. 
Several recent studies, however, have shown that the integrase from bacteriophage φC31 confers 
genomic integration of plasmid DNA and long-term expression in mammalian cells in a variety 
of contexts. Used together, EP-mediated transfection and φC31 integrase could be a powerful 
combination for long-term, nonviral gene therapy.34, 35 
ELECTRON AVALANCHE TRANSFECTION AND ELECTROSONOPORATION 
Improvements in EP methods, equipment, and protocols are inevitable and there have 
been numerous alterations in EP technique and attempts to understand the mechanisms 
underlying EP in recent years.  An interesting recent example of a technique based on EP that 
has been used for gene therapy in rabbit eyes, is EAT.   In electrosonoporation, an electric field 
with high voltage amplitude is produced from microelectrodes adjacent to plasma bubbles or 
blebs (between the retina and choroid in this study).  This forms a transient vapor cavity in the 
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plasma space which is ionized, allowing conductance from the electrode through the vapor cavity 
to the tissue. At the same time, the cavitation bubble generates a propagating acoustic wave that 
exposes the tissue to mechanical stress synchronized with an electric field.  In initial studies on 
chorioallantoic membrane, electron avalanche transfection was >10,000-fold more efficient and 
produced less tissue damage than conventional EP.  Efficient plasmid DNA transfer to the rabbit 
retina after subretinal DNA injection and trans-scleral EAT was also demonstrated in this study. 
Electroretinograms and histology showed no evidence of damage from the procedure.36 
  EAT differs from conventional EP by using microelectrodes instead of large electrodes; 
by relying on ionization of the vapor cavity to deliver the electric field and mechanical stress; 
and by using short, biphasic electric pulses.  Since arc production is considered detrimental in 
conventional EP, EAT delivers the electrical charge via an ionized vapor cavity which prevents 
arc generation, allowing use of much higher electric fields.  Furthermore, short, biphasic pulses 
cause little or no muscle movement which is desirable for precision and patient comfort.  
Increased EP efficiency under the tensile stress created during EAT may occur because of 
increased lipid bilayer instability and resulting increased susceptibility to permeabilization.36 
Another modification of EP, electrosonoporation (ES) is similar to EAT in that EP is 
combined with a physical method of inducing pore formation through interaction with cavitation 
bubbles. Sonoporation (SP) uses ultrasound to temporarily permeabilize cell membranes 
allowing uptake of compounds from the extracellular environment; since membrane alteration is 
transient, the compound is left trapped inside the cell after ultrasound exposure.  Ultrasound 
produces microscopic cavitation bubbles within the extracellular milieu; the cavitation bubbles 
implode producing a shockwave while on or near the surface of a cell membrane; and the tiny 
shockwave produces pores in the cell membrane allowing compounds to diffuse into the cell.37  
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Steps in ES include preparation of a DNA-microbubble preparation, injection, and tissue 
ultrasound exposure.37   
Ultrasound offers good penetration through soft tissue, minimal damage to cells/tissues, and 
does not damage DNA; however, it is limited by breakdown of cell cytoskeleton which among 
other perturbations, alters DNA trafficking within cells.38   
Combining EP with SP has been used in multiple studies for gene transfer and has been 
found to be effective.39, 40  When used to transfect the luciferase reporter gene into muscle, ES 
was found to be twofold more effective than EP alone.40  The following table (table 1) has a brief 
comparison of some of the benefits and shortcomings associated with these techniques. 
Regardless of how poration occurs, persistent, high-level gene expression remains a 
challenge.  This is particularly true for secreted proteins because of their immunogenicity. Our 
results suggest that the secreted alkaline phosphatase (SEAP) reporter gene maintains long-term 
expression at a level of 5 ng/mL in blood, but expression is shut down rapidly after exceeding 
this level following IM delivery of SEAP gene via EP (Figure 1).  This observation is most likely 
due to development of an immune response, since a titer of anti-SEAP antibody was detected in 
the animals expressing a high level of SEAP. Other mechanisms such as death of the cells with 
high reporter gene expression may also contribute. 
EP FORMULATIONS AND NOVEL EP PARAMETERS 
 Although EP is the determining factor that dictates gene transduction in vivo, the 
carrier solution in which genes are delivered by EP can affect the efficacy and damaging effects 
of EP.  Physiologic saline is most commonly used, and when combined with EP, expression of 
luciferase is enhanced by 10,000 fold over direct injection in muscle.41   In tumors, expression 
after EP of luciferase gene in saline was increased 1200 fold.42   Alternatively, concentrated 
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Table 1. Summary Comparing Different Poration Gene Transfection Techniques 
 
Method Advantages Disadvantages References
EP  Equipment is readily 
available & currently in 
clinical use 
 Short-term gene expression 
may be an advantage in some 
settings (cancer therapy) 
 Large amount of literature 
pertaining to optimization & 
implementation 
 Proven in a variety of 
species with numerous 
transfection products 
 Local tissue damage may 
offer advantages in terms of 
cytokine release 
 Inhibition of angiogenesis & 
local tumor destruction 
 Mild transient discomfort at EP 
site & mild local tissue damage 
 Long-term gene expression 





SP  Simple 
 Equipment readily available 
& currently in clinical use 
 Minimal damage to tissues 
and DNA 
 Breakdown of cell cytoskeleton 
alters DNA trafficking 
 Long-term gene expression 
remains a challenge 
 Limited species and genes tested 
 Lack of tissue damage may limit 
release of beneficial cytokines 
[33, 34] 
EAT  Minimal tissue damage 
(applicable to sensitive neural 
tissue) 
 High efficiency of 
transfection (greater than 
10,000 fold more effective 
than EP) 
 Minimal patient discomfort 
 High precision 
 Specialized equipment 
 Cumbersome for clinical use & 
requires specialized training to 
implement 
 Long-term gene expression 
remains a challenge 
 Limited species and genes tested 
 Lack of tissue damage may limit 
release of beneficial cytokines 
[32] 
 
ES  More effective transfection 
than EP alone in one study 
 
 Combination equipment is not 
currently in clinical use 
 Long-term gene expression 
remains a challenge 
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glutamate is one example of the increased efficacy, without toxic effect, that may be provided by 
adding polymers to the DNA formulation; 6 mg/ml of ploy-L-glutamate has consistently 
improved EP efficiency by 4-12 fold.45, 49  In the case of poly-L-glutamate, these effects are 
thought to be a result of its ability to decrease DNA clearance and increase DNA stability in 
muscle.45, 49  Poloxamer 188 provides an example of a polymer which has been added to decrease 
EP damage.50  Perhaps most promising, are the cationic liposomal formulations that have been 
shown to increase transfection in a variety of mouse tumor systems.52  Addition of adjuvants to 
the formulation can increase vaccine efficacy and will be discussed in the vaccine application 
section of this review. 
The actual EP parameters and conditions are as important as or more important than the 
nucleic acid formulation for effective electrotransfection.  Aside from the desirability of having 
adaptive constant-current EP discussed previously,53 longer duration electric pulses with lower 
voltage have been shown to give the same EP effect as high voltage shorter duration pulses.  
Specifically, a pulse of 100 V/cm lasting 100 ms yields expression equivalent to 25 V/cm for 160 
ms.54   Thus, to minimize tissue injury, lower voltages can be used to decrease heat build-up and 
resultant necrosis. In other studies, Satukauskas, et al., have shown that a train of long identical 
pulses, or combinations of pore-creating high-voltage, short-duration electric pulses and 
electrophoretic low-voltage, long-duration electric pulses are necessary for efficient gene 
transfection.55, 56  More recently, Andre’, et al., demonstrated high level gene expression in 
muscle by delivering a single 800 V/cm, 100 microsecond pulse, followed by four 80 V/cm, 100 
millisecond pulses.57, 58   Furthermore, when these investigators examined the effect of fast 
versus slow injection of transfection medium, they demonstrated that very fast injection of 
transfection medium into tissue (20 ul/2 sec) increases gene expression by 500-fold compared to 




APPLICATION OF EP IN LARGE ANIMALS  
Until now, in vivo EP has been primarily conducted in murine models, but attempts and 
applications to large animals have gained momentum in recent years.  Most applications in large 
animals use muscle as the target tissue.  As alluded to previously, skeletal muscle is an ideal 
tissue for EP-mediated gene transfer.  Muscle fibers are long-lived post-mitotic cells, and muscle 
is well vascularized, allowing efficient transport of gene products into the systemic circulation.   
Access to numerous muscle groups is also relatively easy in most species.  Furthermore, gene 
expression in muscle after EP-mediated gene transfer has been reported to be as long as 9-19 
months.42, 60, 61  Thus, skeletal muscle-targeted EP has been used for introduction of numerous 
genes to supplement production of critical secretory molecules in deficient hosts or augment 
levels of gene product already present.    
Perhaps the largest amount of work using EP-mediated gene therapy in large animals has 
been conducted optimizing EP parameters in pigs.  Bureau, et al. demonstrated efficient EP-
mediated transduction of growth hormone releasing hormone (GHRH) gene using electric pulses 
of low field intensity.  They also found that internal needle electrodes give a 25-fold increase in 
expression levels compared with caliper electrodes in skeletal muscle in swine, and demonstrated 
that by optimizing the EP method, favorable physiological changes, such as enhanced weight 
gain and improved body composition, could be obtained at extremely low plasmid doses in a 
large mammal.  Furthermore, they found that the degree of permeabilization of the muscle cells 
is dependent on the electric field intensity, length of pulses, shape and type of electrodes.62  
Somiari, et al. found that cell size was also an important parameter in determining degree of 
permeabilization.63 Use of needle electrodes in large mammals, such as pigs or humans, is 
necessary because of the increased resistance of the skin, the thickness of the subcutaneous fat 
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tissue, and the concern for tissue damage if the intensity of the electric field were to be 
proportionally increased using caliper or plate-type external electrodes.43  Brown, et al. further 
optimized muscle EP-mediated gene transfer by determining that using constant current pulses, 
between 0.4 and 0.6 A applied 80 seconds after injection of 0.5 mg plasmid DNA expressing 
secreted embryonic alkaline phosphatase reporter gene in a total volume of 2 mL produced the 
highest level of expression in semimembranosis muscle in pigs.  Increased injection volumes and 
increasing lag time between injection and EP did not improve transfection efficiency.64   
Numerous other studies have applied EP-mediated gene transfer in pigs with excellent 
results.  The bulk of applications thus far have been directed at regulating fat and muscle mass.  
Draghia-Akli, et al.  note that EP-mediated gene transfer is particularly appropriate for 
modulating the intrinsic properties and mass of muscle and fat.  Treatment conditions such as 
cachexia associated with chronic diseases, autoimmune diseases (e.g., myasthenia gravis), 
stimulation or suppression of appetite, and in vivo manipulation of glucose metabolism and fat 
deposition in patients with diabetes are some of the applications of EP-mediated gene therapy in 
muscle.  Basic studies of muscle-specific transcription factors and their impact on development, 
also benefit from use of EP-mediated gene therapy.   Additionally, it has recently been suggested 
that administration of the gene for leptin, a hormone predominantly produced by adipocytes and, 
functionally, a key regulator of body weight, may ameliorate obesity from a variety of causes.65  
Young pigs that underwent muscle EP with GHRH plasmid had significantly greater 
weight gain, significantly increased lean body mass, and decreased fat mass when compared with 
controls.   Additionally, pigs undergoing EP with GHRH plasmid were leaner at end of study 
than controls, and had a proportional increase in all internal organs and higher bone density.43  
Similarly, pregnant sows treated with GHRH gene IM EP had offspring with optimal health and 
growth characteristics and significantly reduced morbidity and mortality.  Treated pigs also 
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expressed GHRH for at least one year, and beneficial effects on offspring occurred for three 
consecutive pregnancies.66  
Similarly, a study of GHRH gene IM EP in thirty-two Holstein heifers yielded cows with 
improved immune function, health status, significantly increased body weights at 100 days of 
milk production, and improved body condition scores.67   
Myogenic plasmid containing GHRH has also been delivered by muscle EP in severely 
debilitated dogs with naturally occurring tumors, and yielded significantly increased 
concentrations of IGF-1 and increased muscle mass.68  Similar to the previously mentioned work 
by Andre’, et al., work in dogs demonstrated that a combination of 1 high voltage pulse (600 
V/cm, 100 μs), followed by 4 low voltage pulses (80 V/cm, 100 ms, 1 Hz) yielded the same 
transfection efficiency as the standard trains of low voltage pulses, and was able to yield 
detectable systemic expression of human interleukin-12.   Only mild and transitory local side 
effects, without clinically detectable systemic side effects, were seen, indicating that 
electrotransfection is a feasible, effective, and safe method for muscle targeted gene therapy in 
dogs, which could have potential for clinical applications in small animal veterinary practice.69  
In other applications of muscle EP in dogs, Fewell et al. were able to produce measurable 
levels of factor IX in treatment of hemophilia B and described a method for producing high 
transfection efficiency with high levels of systemic factor IX following a single administration;16, 
17 Draghia-Akli, et al. were able to demonstrate effects of GHRH in young, healthy Beagles;70 
and Tone, et al. were able to demonstrate long-term gene expression in muscle EP in dogs.61  
Electrotransfer of plasmid DNA into skeletal muscle has been successfully achieved in 
many different experimental animals including mice, rats and rabbits,41, 71 cattle,67, 72 goats,72 
sheep,73 pigs,74, 75 dogs,17, 68 and monkeys.76  As in the dog studies previously mentioned, it has 
been shown that a better transfection efficiency can be achieved using combination of one high 
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voltage electric pulse followed by different numbers of low voltage electric pulses.56 It has been 
hypothesized that the high voltage pulse first causes permeabilization of cell membrane, 
followed by electrophoresis of DNA across destabilized cell membrane during the low voltage 
pulses.56, 62, 77  Large animal models and production use of EP-mediated gene therapy is growing 
significantly; applications of EP in general seem almost limitless, including the use of EP-
mediated vaccine applications. 
APPLICATION OF EP FOR DNA VACCINES – OPTIMIZATION 
Vaccines (biological agents capable of triggering specific immunity against infectious 
diseases or cancer) can be delivered in a variety of ways, including EP.  They can be categorized 
as inactivated/killed, attenuated/live, toxoid, component, and gene-based (DNA, RNA, 
oligonucleotides) vaccines that can be administered for a variety of purposes.  These purposes 
were historically limited to infectious disease prevention, but now include tumor vaccine 
development and use in a variety of immune-mediated degenerative diseases.  Of the different 
types of vaccine and their different targets, perhaps use of genetic vaccines as applied to both 
tumor vaccines and vaccination for infectious diseases shows the most promise when combined 
with EP.   
Gene vaccines evolved from revolutions in molecular engineering and gene delivery, and 
their usage has become commonplace over the last few years.  Gene vaccines use DNA to 
express immunogen and induce an immune response.  Various gene delivery approaches are 
available to administer gene vaccines which, similar to other gene therapies, can be categorized 
as viral and non-viral.  As stated previously, the use of viral vectors can be very effective in 
transfecting cells and inducing an immune response, but is limited by safety issues.  Injection of 
naked DNA vaccine is safe, and in muscle yields long-term gene expression, but very little 
antigen response is produced.78   DNA injection followed by EP is much more effective, and 
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induces a similar level of immune response as protein immunization. 79 Despite some early 
experimental successes, developing safe and effective DNA vaccines requires optimization of 
several variables before widespread EP-mediated gene vaccine administration becomes 
commonplace.   Ultimately, the simplicity and effectiveness of genetic vaccination using EP may 
allow widespread use of gene vaccination in large animals and humans in the near future.  
Optimization of gene construction can markedly enhance transfection efficiency and 
resulting immune responses when applied to DNA vaccines. To be an effective vector, plasmid 
DNA should contain a strong viral promoter and a strong polyadenylation transcription 
termination signal. Additionally, most vaccination vectors also contain an intron to increase 
expression. When the whole antigen is toxic or immunosuppressive, epitopes from the antigen 
may be utilized and can be expressed as mini-genes, which are inserted into unrelated but highly 
immunogenic sequences that successfully induce both cellular and humoral responses.  
APPLICATION OF EP FOR DNA VACCINES – MUSCLE VERSUS SKIN 
Optimization of EP parameters can also improve the outcome of genetic vaccine. As 
noted previously, to select optimal parameters for EP-mediated DNA delivery in vivo, specific 
needs for different tissues, vaccine formulations, and DNA dosages must be considered 
simultaneously. Also noted previously, muscle is the most commonly targeted tissue for EP-
mediated gene delivery because of, among other reasons, the large quantity of tissue and its rich 
blood supply which allows systemic circulation of secreted proteins.  For vaccination, EP-
induced muscle cell damage may be beneficial because of the release of a variety of cytokines 
which may help initiate immune response by attracting antigen presenting cells (APCs) to the 
injection site.73 Muscle selection is also important; aside from accessibility, muscle should be 
chosen based on EP efficiency difference in different muscles.  For example, in mice the anterior 
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tibialis muscle has been demonstrated to have the highest expression of muscles tested for 
secreted alkaline phosphatase.53 Unfortunately, even when all the aforementioned factors are 
optimized, IM administration of gene vaccine may produce a less than optimal immune response 
in some circumstances.53 
Skin is a more traditional target tissue for vaccination because it is readily accessible and 
has a large population of unique antigen presenting cells.  Keratinocytes are primarily 
responsible for transgene expression after intradermal (ID) administration.80  Expression of 
immunogen by keratinocytes can induce an immune response through interaction with bone 
marrow-derived dermal Langerhan’s cells and dermal dendritic cells.81  Similar to the findings of 
enhanced IM expression of genes when delivered by EP in muscle, 100 to 1000-fold higher gene 
expression was induced after ID delivery of plasmid DNA when introduced by EP.  Specifically, 
higher levels of prostate-specific antigen (PSA)-stimulated CD8+ T cells were induced after 
intradermal EP delivery of low-dose PSA DNA vaccine in a mouse model.82 Thus, skin 
continues to be a common target of EP-mediated vaccine use now and in the future. 
Conversely, there is some evidence that in certain settings, IM EP does produce better 
immunization than ID EP of gene vaccines.71 The low levels of EP-mediated, gene vaccine-
induced immunity in muscle alluded to before, may be a result of the lack of cytokines released 
by professional APCs.  When expressed immunogen is secreted and taken up by large numbers 
of professional APCs, the APCs present antigen and cross-prime large numbers of cells.83 In 
contrast, ID administration exposes a much smaller number of APCs to transfected cells and 





APPLICATION OF EP FOR DNA VACCINES – ROLE OF ADJUVANTS 
As is the case for traditional vaccines, addition of adjuvant can significantly increase the 
magnitude and duration of vaccine-induced immune response in gene vaccines. 
Lipopolysaccharide (LPS), a component of gram negative bacterial cell walls and potent 
endotoxin, has been used to augment immune responses through toll-like receptor 4 (TLR4).84 
Because granulocyte macrophage-colony stimulating factor (GM-CSF) has a potent effect on DC 
differentiation and maturation, and also on expression of MHC and co-stimulatory molecules, it 
has been utilized as immune adjuvant for vaccine against numerous infectious diseases and 
cancer.85-89  Oligonucleotides are also being investigated as adjuvant with promising initial 
results.90-94  Incorporating adjuvant into the gene construct has been demonstrated in an elegant 
example of enhanced anti-tumor vaccine efficacy using dendritic cells electrotransfected with 
mRNA containing the gene for tumor associated antigens (TAA) linked to mRNA encoding 
ubiquitin. The resulting ubiquitinated TAA product was effectively targeted to the proteasome, 
enhancing degradation of TAA which resulted in more efficient priming of TAA-specific CD8+ 
T-cells.88, 95  
APPLICATION OF EP FOR “CELL VACCINES” 
EP has also been used in the development of “cell vaccines”.  For example, dendritic 
cells have been EP transfected with the gene for tumor-associated antigens ex vivo and 
reintroduced to patients to enhance their anti-tumor immune response.  EP transfection of DCs 
with mRNA results in higher protein expression in DCs than DNA, and carries no risk of 
integration into host genome.  RNA instability can be minimized by modifying the mRNA with a 
3’-poly(A) tail and a 5’ 7-methylguanosine cap. A number of studies have been reported using 
this approach to various antigens such as melanoma, carcinoembryonic antigen,86 human 
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telomerase reverse transcriptase, and HER-2/neu antigen.96, 97 Using this approach for infectious 
disease vaccines has been much less common; nevertheless one recent publication reported 
improvement in hepatitis C prevention using mRNA-transfected DC-mediated vaccine.98  
APPLICATION OF EP FOR DNA VACCINES – LARGE ANIMAL AND PRIMATE 
STUDIES 
 Although active research using EP-mediated gene vaccines has grown exponentially over 
the past few years, most of the research to date has been in small animals.  In general, studies in 
large animals have demonstrated less efficacy than in small animals, but the number of studies 
using large animals pales in comparison to those in mice.   Effective EP-mediated gene 
vaccination in primates has been demonstrated however; Zhao and Xu looked at numerous 
combinations of EP parameters for vaccination against hepatitis B virus (HBV) and found a great 
variation in efficiency depending on the EP parameters selected.99  These authors also provided 
another example of using immune-modulating fusion genes (interleukin-2 and gamma interferon) 
as an adjuvant enhancing immune responses in EP-mediated gene vaccination.99 Thus EP-
mediated gene vaccination shows great promise for achieving high gene expression, efficient 
humoral and cellular responses, and specific protection against antigens, including in more 
clinically relevant species such as the Rhesus macaques used in this study. Furthermore, EP-
mediated gene vaccination has proven safe, stable, easy to manipulate, and relatively 
inexpensive.  
INNOVATIVE APPLICATIONS OF EP GENE THERAPY  
Investigations into treatment of type I diabetes mellitus (T1D) have also used muscle-
targeted gene via EP delivery.  T1D is due to a loss of immune tolerance to islet antigen and 
thus, there is intense interest in developing therapies that can re-establish tolerance. Tolerance is 
maintained by complex mechanisms that include inhibitory molecules and several types of 
23 
 
regulatory T cells (Treg). A major historical question is whether gene therapy can be employed to 
generate Treg cells. Recent studies indicate that gene transfer of immunoregulatory molecules can 
prevent T1D and other autoimmune diseases. In studies by Prud’homme, et al., in vivo EP-
mediated gene transfer was thought to have the potential to be used to perform DNA vaccination 
against islet cell antigens.  When combined with appropriate immune ligands, this would result 
in the generation of Treg cells and protection against T1D.  In vivo, EP can also be applied for 
non-immune therapy of diabetes. It can be used to deliver protein drugs such as glucagon-like 
peptide 1 (GLP-1), leptin, or transforming growth factor beta (TGF-beta). These act in T1D or 
type II diabetes (T2D) by restoring glucose homeostasis, promoting islet cell survival and growth 
or improving wound healing and other complications of T1D.100  
Bone marrow cells, splenocyte and T cells generally are difficult to achieve a high level 
of gene delivery, regardless of gene delivery methods employed. Studies by Tervo, et al. found 
that both EP and nucleofection resulted in high-level transgene expression (up to 60% transgene-
positive T cells) from both small and large green fluorescent protein reporter constructs in 
activated rabbit T cells with moderate cytotoxicity.  Both non-viral gene delivery methods were 
vastly superior to retroviral, lentiviral, or adenoviral transduction approaches.  These studies also 
established conventional EP as an efficient and inexpensive procedure to render primary rabbit T 
cells accessible to rapid functional ex vivo analyses. Furthermore, the viability of electroporated 
rabbit T cells was remarkably high (47±7%); compared to analogous studies conducted in 
primary T cells from rats and mice.101  
In an interesting variant of in vivo  EP using transplantation of autologous hepatocytes 
that underwent EP in vitro, hepatocytes were isolated from a surgically resected liver wedge, 
electroporated with an insulin expression plasmid ex vivo and reimplanted intraparenchymally 
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under ultrasonic guidance into the liver in each of 10 streptozotocin-induced diabetic Yorkshire 
pigs.   Based on positive results, authors concluded that autologous hepatocytes could be 
efficiently, simply and safely modified by EP of a plasmid DNA to express, process and secrete 
insulin.  This strategy achieved significant and sustained therapeutic efficacy, and may have 
broader future applications for the treatment of other acquired and inherited diseases for which 
systemic reconstitution of a specific protein deficiency is desirable. Combining autologous 
hepatocytes with ex vivo gene transfer has several advantages. Using this technique, hepatocytes 
are likely to be of higher quality and can be used fresh (instead of preserved).  This also allows 
use of high voltage EP for transfecting primary somatic cells which otherwise might cause tissue 
necrosis in vivo.  Using autologous cells also overcomes the problem of donor scarcity and 
avoids the need for chronic immunosuppressive therapy.102   
Small double strand RNAs, involved in gene silencing or RNA interference, or closely 
related micro RNAs derived from endogenous hairpin precursors can bind to RNA-induced 
silencing complexes and either degrade messenger RNA, block translation, or otherwise suppress 
gene expression. EP may help overcome the fact that routine therapy or studies with siRNAs is 
complicated by the fact that these highly charged molecules do not easily enter cells.103 
In nonhuman primates, gene targeting can produce animal models for translational 
studies of human diseases. Gene targeting in fibroblasts followed by somatic cell nuclear transfer 
(SCNT) has been successful in numerous large animal species, including primates.  In rhesus 
macaques gene targeting in a primary culture of adult rhesus macaque fibroblasts was 
accomplished by culture of adult male fibroblasts transfected by EP of S-phase synchronized 
cells with a construct containing a SV40 enhancer with human telomerase reverse transcriptase to 
overcome senescence and allow long term in vitro manipulations.104 It is thought that these cell 
lines can be used for the production of null mutant rhesus macaque models of human genetic 
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disease using SCNT technology.105  Null mutant sheep, goats, pigs and cattle have been 
produced using an alternative approach: gene targeting in somatic cells followed by nuclear 
transfer to enucleated oocytes (SCNT; reproductive cloning) whose gene targeting efficiency 
could also potentially be improved using EP.106-115   
UNSOLVED CONCERNS PERTAINING TO EP 
One concern in EP-mediated gene transfer in vivo is the amount of tissue damage 
produced secondary to heat generated.  Draghia-Akli, et al. and others have suggested that 
constant current EP (instead of constant voltage) may reduce tissue damage and contribute to 
overall success.46, 67, 74  Unfortunately, exclusively focusing on using lowered voltage pulses in 
order to decrease cell death through necrosis/oncosis, may not prevent death through cell 
apoptosis which has been shown to take place even with low voltage EP.116  Although most of 
the adverse effects of EP have been characterized in muscle, mild damage has also been reported 
with ID EP, but this damage was resolved within one week of EP.81   Additional means of 
decreasing tissue damage include addition of polymers to the injected DNA formulation, 
alterations in ionic strength and composition, and augmentation of EP with other transfection 
techniques such as sonoporation.  
Pain is another concern in cases of in vivo EP – especially if the technique is to be applied 
clinically to non-anesthetized patients.   In humans, patients describe muscle contractions as 
being surprising, sometimes unpleasant, but not painful.117  Pain from EP is proportional to the 
absolute applied voltage,118 and one way of lowering the total voltage is by decreasing the gap 
between electrodes to 0.4 cm.117  During EP of cutaneous masses, muscle contractions can also 
be palliated by elevating or tenting the skin to be electroporated well above the underlying 
musculature.119   In certain settings, ex vivo EP may be practical, which would allow for the EP 
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procedure to be conducted on cells harvested from the patient for EP, and subsequently 
reintroduced in situ, completely eliminating the chance of EP-induced pain.102 
Vascular effects of EP have also been a concern for many investigators, but recent studies 
suggest that changes in afferent and efferent vessels during EP may be beneficial, particularly 
when applied to tumor gene therapy.  High voltage pulses cause a brief reflex constriction of 
afferent arterioles in normal tissue, and in tumor tissue (which have more fragile and tortuous 
blood vessels) long-term hypoperfusion can occur after EP.120  These vascular effects may be 
beneficial in electrochemotherapy because higher concentrations of drug may remain trapped in 
the tumor due to lack of “wash out” at the time of EP.  Similarly, in gene therapy, transient 
hypoperfusion has been shown to enhance gene expression.121-123   
One of the advantages of using EP and other non-viral vectors is that they are not 
hampered by vector immunogenicity if properly designed (by removal of CpG islands and 
residual bacterial sequences).   If not properly designed, CpG-mediated nonspecific 
inflammatory effects (e.g. mediated through binding to TLR-9) can injure tissues and/or confuse 
the interpretation of immunological studies.  Additionally, many viral promoters are turned off 
by inflammatory cytokines.124-126  Another approach to minimize immunogenicity is to delete 
most vector elements producing “minicircles” containing the expression cassette.127  
Furthermore, if the gene being transfected is to be secreted, signal peptide sequences may also 
play an important role in functional expression.  For example, studies involving nonhuman 
primates that received an erythropoietin encoding plasmid showed that changing the transgene 
leader sequence and optimizing the gene codon usage yielded higher levels of circulating 
transgene product and a more significant biological effect than the wild-type gene.76  Thus, by 
altering the plasmid or transfected DNA design and sequence, one can minimize the dose 
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necessary to attain physiological levels of the target hormone, enzyme, or peptide, and 
manipulate the expression of the newly produced transgene product.  
CONCLUSION 
 In summary, in vivo EP-mediated gene therapy is gaining ground as one of the most 
important means for non-viral gene therapy.  Further understanding of the mechanisms of target 
cell DNA entry, intracellular DNA transport, and nuclear processing will allow further 
optimization of the technique through optimization of gene formulations and electrical pulse 
parameters.  Furthermore, the ability to augment EP with tension forces (in EAT and ES), use it 
in an ex vivo setting, and incorporate integrase enzyme to allow genomic integration of 
transfected genes may broaden the appeal of this technique.  At this point, there appear to be few 
limitations, and potential uses continue to grow as these limitations are overcome.  
 Because of the multitude of advantages in using EGT to attain gene expression, we have 
chosen this as our gene transfection method of choice for cancer immunogene therapy.  In the 
next chapter, we discuss the effectiveness of using EP-mediated gene transfection of interleukin-
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As noted in chapter 2, electroporation (EP) is the application of a series of square-wave 
electrical pulses to increase cell permeability and allow movement of molecules into cells.  
Several recent reviews describe application of this technique to gene 2, 12-15 and drug therapy15, 
128-131.  Over the past fifteen years, EP has become a common technique for introducing large 
molecules into cells, both in vitro and in vivo.   
IL-12 treatment can have a dramatic anti-tumor effect on a variety of neoplasms 132-137.  
Both innate resistance and adaptive immunity are affected by IL-12 mediated anti-tumor 
resistance. IFN-gamma and other cytokines induced by IL-12 either directly, or indirectly 
through other cytokine signaling, have both direct toxic effects on the tumor cells, and potent 
anti-angiogenic activity on tumor neovasculature. IL-12’s action in adaptive immunity relies on 
its ability to trigger or augment Th1 and CTL responses. Thus IL-12 has a potent adjuvant 
activity in cancer therapy and in vivo electroporation delivery of genes or electrogenetherapy 
(EGT) has been described in numerous tumor-bearing murine models and in early human trials 
18, 138.  In these studies, IL-12 EGT eradicates tumors and induces long-term anti-tumor memory, 
but is unable to eradicate large tumors 138.   
BLM, an antitumor antibiotic, causes breaks in double-stranded DNA and releases free 
radicals which cause cellular oxidant damage 139. Delivery of BLM by local electrochemotherapy 
(ECT) is an ideal way to increase efficacy while reducing potential toxic side effects.  Once 
BLM enters tumor cells during ECT, it becomes sequestered because of its large size and lack of 
transmembrane transporters. This sequestered site prevents non-target organ toxicity and allows 
specific targeting to the local EP site.  In experimental animal models, delivery of BLM via 
intratumoral ECT consistently eradicates large tumors but often fails to extend survival time over 
standard therapy.  EP delivery of chemotherapeutics has been described in animals for the 
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treatment of SCC in cats 140 and a variety of cutaneous and subcutaneous tumors in cats, dogs, 
and horses 131.  Bleomycin ECT has also been well tolerated in humans with between 9 and 
100% complete response rates depending on the technique used.141  In fact, the European 
medical community has embraced ECT for many years, as evidenced by the results of the 
European Standard Operating Procedures of Electrochemotherapy (ESOPE) trials completed in 
2003.  These trials demonstrated that ECT was not only safe and effective, but also efficacious 
for local control of a variety of tumors.142  Two of the limitations of ECT are that it is currently 
only suitable for local treatment of superficial tumors, and it only targets the primary tumor.142 
Thus the combination of BLM, which is able to eradicate large primary tumors, and the 
gene for IL-12, which can induce anti-tumor immunity, seems ideally suited for treatment of 
most neoplasia which is accessible to local treatment.  In fact, we and others have previously 
demonstrated that this combination can successfully eradicate and prevent recurrence of 
mammary cancer and melanoma in mouse tumor models 138, 143.  In addition to being efficacious, 
this treatment appears to be well-tolerated, has minimal side effects, preserves tissue 
architecture, and could be easily adapted to clinical use.  However, this combination has not been 
tested in large animals bearing naturally occurring tumors, nor has it been used in humans at this 
point.  In order to determine whether experimental results translate into positive clinical results, 
we used ECGT to treat six client-owned dogs with a variety of tumors. 
MATERIALS AND METHODS 
Selection of Naturally Occurring Tumor-Bearing Dogs.  Privately owned dogs that 
were referred to the Cancer Treatment Unit of the Louisiana State University’s (LSU) Veterinary 
Teaching Hospital and Clinics were selected for the study from 2004 to 2008.  Aside from 
having histologically confirmed neoplastic disease, inclusion criteria included the absence of 
overt heart, renal, or other life-threatening illness.  Dogs were staged by obtaining a thorough 
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anamnesis, physical examination, complete blood cell count, serum biochemistry profile, 
urinalysis, electrocardiogram, thoracic radiographs (three view metastasis check), and abdominal 
ultrasound if indicated.  Additionally, two of the dogs had computerized tomography (CT) 
scanning of the skull to gauge the degree of local tumor invasion and bone lysis. 
In Vitro IL-12-Augmented Cytotoxicity Determination.  A SCC cell line (SCCVII) 
was transfected with either two micrograms fIL-12 DNA or control DNA by in vitro EP, grown 
for 24 hours, and conditioned medium was collected.  DNA was prepared using endotoxin-free 
preparation kits (Qiagen, Germantown, Maryland) using the standard protocol provided by the 
manufacture. Leukocytes were harvested from pre-treatment blood samples obtained from the 
second SCC-bearing dog.  Leukocytes (5 x 105) were then added to 1.5 mL of the conditioned 
medium and incubated for 18 hours at 37oC .  Conditioned leukocytes were then mixed in a 50:1 
ratio with fluorescent-labeled canine osteosarcoma target cells (D17) and incubated for 24 hours 
at 37oC.  The number of remaining fluorescent cells (live cells) per microliter were then counted 
and compared to numbers remaining with control DNA. 
 Imaging.  Except for abdominal ultrasound on the dog with histiocytic sarcoma, dogs 
were anesthetized for CT scans.  An intravenous catheter was placed in the cephalic vein and 
maintenance fluids were delivered during anesthesia.  Dogs were premedicated with various 
combinations of anxietolytic, analgesic, and parasympatholytic drugs, induced with propofol, 
intubated, and maintained on isoflurane in oxygen.  Hemoglobin oxygen saturation, blood 
pressure, and electrocardiography were monitored during anesthesia. 
 For staging via thoracic radiographs, ventrodorsal, left lateral, and right lateral 
radiographs were obtained using digital radiography equipment (Siemens Medical Solutions 
USA, Incorporated, Malvern, Pennsylvania) and were evaluated by boarded veterinary 
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radiologists.  For CT scans of the first SCC dog, a single slice spiral CT scanner (Picker PQ-
5000, Picker Corporation – now GE Healthcare, Waukesha, Wisconsin) was used.  For the 
second SCC dog, a 16-slice volume CT scanner (Lightspeed VCT, GE Healthcare, Waukesha, 
Wisconsin) was used.  Abdominal ultrasound was also performed by a boarded veterinary 
radiologist and utilized a Logiq 9 ultrasound machine (GE Healthcare, Waukesha, Wisconsin).  
 Other Diagnostics.  For clinicopathologic data, routine jugular phlebotomy and 
collection into EDTA blood and serum separator tubes were used to determine complete blood 
counts (CBCs) and serum chemistry analyses.  Blood was run on an automated ADVIA 120 
hematology analyzer with multispecies software (Bayer, Fernwald, Germany) and blood smear 
differential were confirmed manually.  Serum was run on an Olympus AU640e automated 
chemistry analyzer (Olympus Incorporated, Center Valley, Pennsylvania).  Urine was obtained 
by cystocentesis and routine urinalyses consisted of determining urine specific gravity, urine 
dipstick analytes, and sediment examination.  In the case of the histiocytic sarcoma dog this was 
followed by routine urine culture and sensitivity. 
 For confirmation of tumor type, excision biopsies from the primary tumor were obtained 
surgically under anesthesia and were placed in 10% neutral buffered formalin.  After being fixed, 
tissue was cut-in, paraffin embedded, sectioned at 3 µm, adhered to slides, stained with 
hematoxylin and eosin, cover-slipped, and evaluated by boarded veterinary pathologists.  
 Treatment.  An intravenous catheter was placed in the cephalic vein and maintenance 
fluids were delivered during anesthesia.  Dogs were premedicated with various combinations of 
anxietolytic, analgesic, and/or parasympatholytic drugs, induced with propofol, intubated, and 
maintained on isoflurane in oxygen.  Hemoglobin oxygen saturation, blood pressure, and 
electrocardiography were monitored during anesthesia.  Between 0.5 and 2.0 IU BLM (Bleo, 
Teva Parenteral Medicines, Incorporated, Irvine, California) and 150-400 µg fIL-12 DNA were 
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administered in 1-2 mL of 0.45% NaCl injected parenterally into the center of the mass, 
immediately followed by insertion of a hexagonal array of six needle electrodes (Inovio 
Biomedical Corporation, Blue Bell, Pennsylvania) surrounding the injection point (trans-
lesionally) and electroporation.  The only exception was the first case of SCC where simple 
caliper electrodes were used to deliver the pulses.  Two 20 msec 400 V/cm electrical pulses were 
administered 100 msec apart using an ECM 830 electroporator (BTX, Genetronics – now Inovio 
Biomedical Corporation, Blue Bell, Pennsylvania).  Additional treatments occurred ten or more 
days after the first.  The number of treatments varied from one to three, and the study was 
approved by the Institutional Review Board of the LSU School of Veterinary Medicine 
 Response to treatment was evaluated through recheck examinations, tumor measurement 
and gross characterization, communication with the pet’s owner, follow-up CBCs and serum 
biochemistry profiles, and in two cases, with follow-up CT scans.  Complete response is defined 
as disappearance of all measurable tumors for 21 days and partial response was defined as more 
than 50% reduction in measurable tumor for 21 days.  Lack of measurable tumor for greater than 
eight months was characterized as a cure for this study.  
RESULTS 
 fIL-12 depicted in figure 2a provided by Dr Stephen Dunham (University of Nottingham, 
United Kingdom) was chosen due to the lack of canine IL-12 availability.  There is 91% 
homology between the canine and feline IL-12 144 suggesting that the fIL12 should be functional 
on canine cells.  To confirm this assumption, the biologic ability of fIL-12 to activate canine 
mononuclear cells was determined.  Canine leukocytes activated by fIL-12 induced significantly 
more (p<0.05) canine target tumor cell death when compared to control DNA (figure 2b).   
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progression of its cholestasis or hypercholesterolemia based on serum chemistries.  In the dog 
with melanoma, alkaline phosphatase increased and was thought to represent increasing primary 
tumor bone involvement or cholestasis; this dog’s neutrophilic leukocytosis also progresses 
slightly and was thought to be related to increased necrosis and ulceration of the primary tumor.  
It is worthwhile noting that both these dogs had significant changes prior to treatment; therefore 
it is not thought that ECGT played any role in progression of pre-existing disease.  
Table 2:  Summary of clinicopathologic abnormalities and side effects of treatment: 
Signalment 6.5 kg, 8-month-
old, M Shih Tzu 
with maxillary 
SCC 
4.5 kg, 6-month-old, 
F Jack Russell 
Terrier with 
mandibular SCC 
40 kg, 9-year-old, 
FS Rottweiler with 
histiocytic sarcoma 
13 kg, 19-year-old,  
F Chow Chow cross 
w/ metastatic 
melanoma 
37 kg, 9.5-year-old,  








NSF NSF ALP 488 (0-100) 
TB 1.1 (0-0.4) 
Chol 333 (150-240) 
UC: E.Coli 
ALP 269 (0-100) 
Alb 2.4 (2.6-4.2) 
TP 5.6 (5.8-7.5) 
Plat 1003 (220-600) 
WBC 16.2 (8-14.5) 





NSF NSF ALP 535 (0-100) 
TB 1.0 (0-0.4) 
Chol 335 (150-240) 
ALP 399 (0-100) 
Plat 1008 (220-600) 
WBC 18.2 (8-14.5) 





decreased appetite  
None Swollen limb distal 
to tumor 
Diarrhea 2 days None 
 
Alb = Albumin    ALP = Alkaline Phosphatase  Chol = Cholesterol   
F = Female    FS = Female Spayed   M = Male   
Neut = Neutrophils (x103/dl)   NSF = No significant findings  Plat = Platelets x103/dl  
TB = Total Bilirubin    TP = Total Protein   UC = Urine culture   
WBC = White   blood count (x103/dl)  
 
Of the six dogs treated, three had complete responses and three had partial responses.  
The first dog (with maxillary SCC) treated, had a complete response.  This dog was the only dog 
to receive BLM/IL-12 ECGT using caliper electrodes as performed in tumor-bearing mice (17).  
Morphologically and on CT scan, this dog had clear bone lysis and a large tumor initially (figure 





























ure 5a).  By
, most of th
d to surgery
side for a s
 remains tum
: Photograp
t.  a. Pre-tre
fter treatmen
s after treat
 with kind p
 reserved.  N





ed also had 
 electrode (a
 SCC demon







t.  c.  Pre-tr
ment. (Figu
ermission of
o part of th
rm or by any
itten permis
uch of the as
n therapy, t
rt period of 
a complete r
s did all sub
strate mark
 second CT

























e dog with 









is dog was 
s).  CT ima
sion and tum















 tumor free 
































































  Clinical Su
6.5 kg
old, M













.  Pre- and 
air for the d
lar SCC & d
e sections ar
hrough the 
 CT scan.  T
mmary (as
, 8-month-


























F Jack Russell 
Terrier 
 cm diameter SCC













 of incisor a
equentially f
re- and pos
 tumor site 
50 
: 
























































g, 19-year-old,  
ow Chow cross 





s & pulmonary 
T3N2bM1 
iographs show    
nary metastases 
2 ECGT 
 day interval 
icam, tramadol 
 primary tumor 
tion, euthanized 







r the same a
37 kg, 9.5-yea
FS Golden Re















led).  CT 
r to transver















































s periods of 
graph taken
d with ECG
 therapy.  Th
ly leaving n
e (table 3). 











c pain, the c
d functiona
anesthesia, 
 at the time 
T, avoiding 






 resolved).  
g dogs, whic
ere not cand





















s offer a hig





































ffects.  As c















e had less 
t treatments






he tumor).  
 (the gingiva













































e joint in co
 of the prim
 her quality
s. 
oth the dog 
 in tumor si
sponders.  In
ve neoplasti













 of life, she 
with metast
ze by greate















r than 50%  
 the dog wit
d numerous
rosarcoma a






.  b.  Photog
).  
to represent















 scar tissue 
hile not con
 joint was th
ent in this d






















a.   Photogra
























 The effect of treatment on metastatic disease was not determined.  Both dogs with 
metastatic disease prior to treatment, ultimately were euthanized because of complications either 
associated with their metastases or with recurrence of the primary tumor. Generalizations 
regarding the type of tumors amenable to ECGT were also difficult given the small number of 
dogs treated.  As is true with most neoplasia therapies, dogs with advanced metastatic neoplasia 
appear to be poor candidates for ECGT.  At least two types of invasive oral neoplasms, SCC and 
acanthomatous ameloblastoma, responded well to treatment.  
Table 3 summarizes the clinical findings and outcomes for five of the dogs treated.  The 
sixth dog (not included in this table), a dog with fibrosarcoma of the soft palate, had initial tumor 
regression with rapid recrudescence after a single treatment and owners terminated their 
participation in this study. 
DISCUSSION 
As noted by several authors 146, using client-owned dogs for clinical investigation of novel 
cancer therapies offers several advantages over mice and humans.  Compared with humans, dogs 
have similar anatomy and physiology; dogs often share the same environment as humans; dogs 
naturally develop cancers sharing many characteristics with human cancers, the canine genome 
has been sequenced; and cancers in dogs grow over long periods of time yet their growth occurs 
over a short enough time period to be useful in evaluating new therapies.  Dogs also share many 
of the intra-individual variations that humans do, including varied genetic constitution, varied 
immune responses, intra-tumoral heterogeneity, varied development of recurrent or resistant 
disease, and a varied degree of metastatic disease.  Pet dogs also have the advantage of being 
cared for until ages commonly associated with the highest risk for cancer. For many of the 
naturally occurring cancers in dogs, histological appearance, tumor genetics, biological behavior, 
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and response to therapy are similar to their human counterparts.  Furthermore, the lack of 
established “gold standard” veterinary cancer treatment protocols, allows dogs to be treated 
humanely with less proven treatment alternatives not possible in humans 146.  
From this series of treatments in dogs with spontaneous neoplasms and varied genetic 
makeup, environmental conditions, nutrition, and husbandry, we can conclude that the ECGT 
was well tolerated and had minimal side effects.  Additionally, the treatments themselves can be 
easily accomplished with less than fifteen minutes of anesthesia.  While not particularly painful, 
humans receiving EP describe uncomfortable muscle twitching; this discomfort combined with 
the need to access poorly accessible oral sites necessitates general anesthesia.   
ECGT resulted in disease free intervals of greater than eight months in three tumors 
(considered a cure in this study) ; two of which had recurred after attempts at surgical resection 
prior to receiving this ECGT.  Two of these tumors were SCCs which have previously been 
shown to respond to BLM ECT without gene therapy 131; however, the period of follow-up was 
much less than the five cancer-free years that we report here.  We were unable to evaluate 
whether these dogs would have been cured with BLM ECT alone, but theoretically, the 
augmentation with IL-12 gene therapy should help stimulate immune surveillance/memory and 
prevent recurrence as we found in mice (17).  Acanthomatous ameloblastoma has not previously 
been reported to be ECT-sensitive; however, the lack of control subjects did not allow us to 
compare ECT to ECGT for this tumor either.   
The dog with fibrosarcoma did not receive a full series of treatments.  This dog’s partial 
response to therapy suggests that fibrosarcomas may be partially responsive to this treatment 
modality.  In the two dogs with advanced metastatic neoplasia, ECGT enhanced the dogs’ quality 
of life prior to euthanasia; the effect of ECGT on metastatic disease was not determined.  Both of 
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these dogs were not deemed to be candidates for surgery, radiation, or chemotherapy because of 
their advanced disease; thus ECGT offered a safe, relatively non-invasive, method of local tumor 
control without the side effects associated with conventional cancer therapies.    
In humans, the rates of complete response after once-only treatments of single-agent, 
BLM ECT is reported to be between 9 and 100% depending on the technique used. 141  
Electrogene therapy of IL-12 has also reached phase one clinical trials in humans and has had 
similar positive results.  In the first trial of gene transfer using electroporation in humans, the 
therapy was deemed, “safe, effective, reproducible, and titratable.”18  Moreover, IL-12 EGT 
without any other therapy gave complete regression of non-electroporated distant metastases in 
10% of the subjects and produced disease stabilization or partial response in an additional 42%.18  
Although impressive, if these therapies were combined, as in our study, the responses should 
improve significantly based on our findings in dogs and mice.138 
CONCLUSIONS 
 Given the previous results achieved with experimentally induced tumors in mice 138 and 
the encouraging responses achieved in three of the dogs in this study, ECGT offers a promising 
new approach to simple, relatively non-invasive tumor therapy with minimal side effects in dogs.  
Furthermore, ECGT may also be applicable to other species with readily available species-
specific IL-12 DNA.  These early applications support further research and treatment of a variety 
of neoplasms in dogs, and offer great promise for other species, including humans.  For humans, 
additional pre-clinical studies assuring the safety of both EP and gene transfection with IL-12 are 
needed before applying for Investigational New Drug status.  In the next chapter, safety studies 
looking at the toxicity of a tumor targeted version of the interleukin 12 gene were conducted to 
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One of the major challenges associated with traditional surgical oncology, radiation, and 
chemotherapy is tumor recurrence and metastasis.  One strategy to prevent tumor recurrence and 
metastasis is to induce or augment anti-tumor immunity.   Interleukin 12 (IL-12) induces and 
maintains a powerful Th1-mediated anti-tumor immune response and has been used 
therapeutically in humans to treat neoplasia. The major effects of IL-12 are the stimulation of 
IFN-γ production by natural killer (NK) and T cells, which in turn stimulates additional IL-12 
production147, and induction of anti-angiogenesis genes 148.  Another important role of IL-12 is to 
exhibit immunoregulatory functions in the generation of T helper 1 (Th1) and cytotoxic T 
lymphocytes (CTL)149.  For these reasons, daily systemic administration of IL-12 recombinant 
protein (rIL-12) has been shown to generate a significant inhibitory effect on the metastatic 
tumor growth of B16F10 melanoma, established murine renal carcinoma (RENCA), and CT26 
tumors148, 150, 151.  Unfortunately, rIL-12 has also been associated with significant adverse effects, 
including death152, 153.   Investigation of rIL-12 toxicity suggests that cytokine-induced shock 
causing early deaths was mediated by NK cell production of IFNγ 154.  Much of this toxicity was 
attenuated by giving low, “desensitizing” doses of rIL-12 prior to treatment with the normal dose 
regimen; nevertheless, use of rIL-12 has now been supplanted by use of IL-12 gene therapy for 
cancer treatment.  
Systemic administration of cytokines at pharmacologic doses results in high 
concentrations of cytokines in the circulation and often in suboptimal levels in tissues at the site 
of tumors, therefore therapy is more likely to cause systemic toxicity and less likely to be 
efficacious in treating the primary tumor.  In contrast, EP-mediated cytokine gene transfection 
allows localized expression of cytokine at targeted sites, avoiding deleterious side effects and 
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resembling the normal paracrine effect of cytokines.  This localized effect can be enhanced more, 
if the gene is somehow targeted to specific tissue or the tumor itself.   
Our laboratory has previously demonstrated and published the efficacy of intratumoral 
EP of the gene for IL-12155.  Others have also found that therapy using the gene for IL-12 is safe 
and effective in a variety of pre-clinical models along with in human phase 1 trials treating 
melanoma 18.  However, in these safety trials B16 tumor-bearing mice were used, making it 
difficult to extrapolate to IL-12 cancer gene therapy in general (and making it difficult to rule out 
variables associated with tumor burden).   Moreover, the electroporation field in those studies 
was a much higher voltage (1300 V/cm) and shorter duration (95µsec) than the parameters used 
in this study156.  Our laboratory and others have found that lower voltage, longer duration pulses 
are associated with comparable transfection efficiency in a variety of mouse tumor models using 
standard reporter gene assays2, 54, 157.  Additionally, currently available commercial 
electroporators deliver low voltage over longer intervals. 
Safety of EP has also been examined in numerous studies and numerous EP protocols 
have been found to be safe and effective for most commonly used tissues158-160.  There is some 
concern regarding use of EP in heart muscle, and patients with defibrillators or arrhythmias may 
not be good candidates for EP 160.  To our knowledge, nobody has examined the toxic effects of 
EP over time when applied under clinical conditions in a systematic way, nor has anyone 
reported the safety and toxicity of a relatively low voltage, long duration electroporation 
protocol; therefore we sought to characterize EP changes at numerous acute and a chronic end-
points using a clinical electroporator to determine if there was severe or lasting toxicity. 
To increase the efficacy of anti-tumor immune induction and further address the concern of 
safety, we have developed a plasmid DNA vector encoding a tumor-targeted peptide linked to 
the IL-12 gene, allowing the gene product to preferentially accumulate in tumors regardless of 
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the site of injection. Pre-clinical therapeutic studies using murine ttIL-12 encoding plasmid have 
been completed in four independent tumor models; we have found that accumulation of IL12 
protein in tumors is safe and triggers a more aggressive anti-tumor immune response than 
systemic rIL-12 therapy (Cutrera, submitted manuscript).   In this study, the safety and toxicity 
of ttIL-12 was thoroughly analyzed (according to FDA guidelines for Investigational New Drug 
(IND) approval) in order to determine whether this novel fusion gene can be safely used in 
humans under clinical circumstances. 
MATERIALS & METHODS 
 GLP or GLP-like Protocols.  Serum chemistries and complete blood counts (CBCs) 
were performed by Antech Diagnostics (Memphis TN), which is fully compliant with Good 
Laboratory Practice (GLP)  Regulations as set forth in 21 CFR Part 58 as well as other regulatory 
requirements.  All other procedures, including tissue archival, quality control, and data keeping 
procedures were conducted in GLP-like conditions (as stipulated by GLP regulations, but not 
certified by the Food and Drug Administration (FDA)). 
Mice. All animal use studies had approval from the Louisiana State University 
Institutional Animal Care and Use Committee (Baton Rouge, LA). This committee follows 
USPHS Policy on Humane Care and Use of Laboratory Animals.  Young adult male and female 
C3H/HeJ mice were obtained from a commercial vendor (Harlan Laboratories, Inc., 
Indianapolis, Indiana), were fed ad libitum a standard diet (Harlan Teklad irradiated mouse diet 
7912, Madison, WI), and were housed in a temperature-controlled animal facility with a 12/12-
hour light/dark cycle.  Each group for the toxicity studies consisted of six male and six female 
mice; the age of mice at the time of the first treatment in this study was 8.5 weeks. 
Cell Lines and Propagation. For tumor resection and wound healing studies, SCCVII 
murine squamous cell carcinoma cells which are syngeneic in C3H mice, originally obtained 
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from Dr Bert O’Malley (Baylor College of Medicine) were maintained as monolayers in 
Dulbecco’s Modified Eagle Medium.  Tumors from study mice were harvested and confirmed to 
be spindyloid squamous cell carcinoma cells based on routine histopathology, cytokeratin 
immunohistochemistry, and transmission electron microscopy.  Cells were harvested from flasks 
using trypsin-EDTA (0.05% trypsin-0.53 mmol/L EDTA; Mediatech), collected by 
centrifugation, and washed.  Cells were counted and their concentration was adjusted to 2 x 105 
cells/ml using sterile phosphate- buffered saline (PBS) prior to inoculation into mice.  
Tumor Inoculation and Monitoring.  Tumor cells were inoculated in syngeneic C3H 
mice by intradermal injection of SCCVII cells in the caudodorsal skin.  30 µl of approximately 2 
x 105 SCCVII tumor cells in sterile PBS was delivered to each mouse.  Tumors were monitored 
using a digital vernier caliper and volumes were calculated using the formula 4/3π(a2 b) where 
“a” is the tumor long dimension (diameter) and “b” is the shortest measurement perpendicular to 
“a”. 
Anesthesia.  For all procedures requiring anesthesia, mice were anesthetized by chamber 
induction with 4% isoflurane in oxygen and were subsequently maintained by mask 
administration of isoflurane in oxygen to effect.  During longer procedures, an infrared heat lamp 
was used for thermal support.   Respiratory effort and rate along with anal tone and withdrawal 
reflexes were monitored throughout anesthesia. 
Tumor Resection Surgery.  When tumor areas averaged 30,000 mm3, mice were 
anesthetized, the area surrounding the tumor was clipped to remove hair, and the surgical site 
was prepared with three alternating 70% ethanol/2% chlorhexidine scrubs.  The site was draped 
with a sterile drape and an elliptical incision was made with minimal tumor margins 
(approximately 1 mm – no effort was made to completely excise tumors beyond a minimal 
64 
 
margin) and the tumor was removed.  The skin defect was closed with 2-3 cruciate sutures of 5-0 
silk.  
Plasmid.  DNA encoding the tumor-targeting peptide (CHP) was inserted into the murine 
IL-12 gene construct immediately upstream to the p40 termination codon (Cutrera, submitted 
manuscript).  This gene construct expressed CHP-IL-12, herein referred to ttIL-12, and was 
inserted into a pCLneo mammalian plasmid expression vector (Promega Corporation, Madison, 
Wisconsin). 
Electroporation.  Either skin overlying the dorsal lumbar epaxial musculature or 
quadriceps femoris muscle were electroporated using a fixed-voltage, four-needle array 
disposable electrode with a 4 mm gap delivering two 60 ms pulses of 46 V (200 V/cm) spaced 
approximately 190 ms apart, attached  to a Medpulser™ (Inovio Incorporated, San Diego, 
California) clinical electroporator.  For SC application (the first treatment), either 30 µL of 
0.45% saline or ttIL-12 in  0.45% saline were injected subcutaneously; within 15-20 seconds the 
electrode was inserted transcutaneously straddling the injection site; and the pulses were 
delivered.  For IM use, the same volume was injected bilaterally in the quadriceps muscles (the 
total volume was therefore 60 µL, and the total DNA was divided between the two limbs), 
followed by insertion of the electroporator needles deep into the musculature surrounding the 
injection site. 
Toxicity Study.  Groups of six female mice and six male mice divided equally between 
no treatment controls, 0.45% NaCl EP, 1 µg ttIL-12 DNA in 0.45% NaCl, and 5 µg ttIL-12 DNA 
in 0.45% NaCl were treated.  The volumes injected were 30 µL in the case of SC treatment and 
60 µL divided bilaterally into two 30 µL aliquots for IM treatment.  Treatment consisted of 
initial SC EP followed ten days later by IM EP.  Control and treatment groups were then 
sacrificed at acute time points (1, 3, and 7 days) and a 30 day chronic time point.  
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Dosages of ttIL-12 were a presumably toxic mega-dose of 5 ug IL12 DNA and a therapeutic 
dose of 1 µg IL-12 DNA.  The presumed toxic dose was chosen for determining the toxicity limit 
but will not be translated to humans because it would equal an impractical  22.5 mg in a 90 kg 
human (requiring a minimum injection of approximately 25 mL). The therapeutic dose chosen as 
most likely to be translated into human trials is 1 µg for multiple administrations, which is equal 
to 4.5 mg in a 90 kg human. 
Surgery Augmented with ttIL-12 EP Study.  To examine the effect of ttIL-12 EGT on 
recovery from tumor resection surgery, groups of six male mice were treated with the 
aforementioned protocol, but a massive dose of 20 µg of ttIL-12 was administered during each 
episode of EGT.  
Physical Exam/Behavior Monitoring.   A brief physical exam including body weight, 
respiratory rate and effort, mucus membrane character, cutaneous lesions, musculoskeletal 
changes, and localized tissue damage was performed on each mouse the day after EP and every 
seven days thereafter.  Mice were also monitored for gait abnormalities and grooming behavior 
along with any other detectable behavioral anomalies.  
CBC & Chemistry Analysis.   Mice were anesthetized and the brachial artery was 
accessed through an incision created in the ventral axilla; the artery was severed and pooled 
blood was collected with a sterile glass pipette.  Approximately 400-600 µl of blood was 
collected into a miniature EDTA tube (BD Microtainer™ Tubes, Becton, Dickenson and 
Company) and mixed well.  The remaining blood – usually approximately 800 µL – was 
collected into a miniature plasma separator tube (BD Microtainer™, Becton, Dickenson and 
Company) and thoroughly mixed.  A blood smear was made from the EDTA blood sample and 
the remaining blood and plasma were sent to a private GLP lab (Antech Diagnostics, Memphis, 
Tennessee) for a CBC and select chemistry analysis. 
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Euthanasia and Gross Necropsy.   Under isoflurane general anesthesia, mice were 
exsanguinated and death was assured through cervical dislocation.  All mice received a complete 
necropsy.  Any tissue which had gross lesions (in addition to those routinely collected) was 
saved and processed for histopathologic examination. 
Histopathology.  All major perfused organs as well as any tissues with lesions (2 
sections of skin) were fixed in 10% neutral-buffered formalin.  Routine tissues examined 
histologically on all mice were liver, spleen, kidneys, lungs, heart, thymus, tracheobronchial 
lymph nodes, brain, bone marrow (lumbar spine & femurs), and quadriceps musculature.   After 
fixation the tissue was cut-in, embedded in paraffin, sectioned on a microtome, mounted on glass 
slides, and stained with hematoxylin and eosin.  Cover-slipped slides were examined by a 
pathologist and lesions were recorded.  All slides and paraffin blocks were subsequently 
archived. 
Statistical Analysis.  Groups in each phase of evaluation were compared to control mice 
using a two-tailed paired T-test with a confidence interval of 95%.  Charts of group means 
include standard error bars unless indicated otherwise. 
RESULTS 
Optimization of Medpulser™ Parameters.  Our ultimate goal is to effectively deliver 
ttIL-12 gene to tumors, tissues at the margins of tumors, or systemically via musculature using 
EP in order to prevent tumor recurrence after primary tumor ablation.  To achieve this goal, it is 
important to have a set of EP parameters enhancing gene delivery in multiple tissues.  To 
determine such a set of parameters, we compared each of the clinically used applicators provided 
by the manufacturer (Inovio, San Diego, California) of the electroporator used in this study.   We 
found that using the Medpulser™ fixed-voltage applicator delivering 107 V/cm for two 
consecutive 60 msec pulses separated by a pause of approximately 190 msec allowed statistically 
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significant (p = 0.002 and p < 0.001) high levels of reporter gene and cytokine expression when 
delivered both SC and IM (Fig. 8A).  This applicator delivers 46 V across a 4 mm gap, four-
needle electrode array that is inserted transcutaneously. 
Cytokine Expression after ttIL-12 EGT.  In previous use of rIL-12, toxicity of IL-12 
protein was seen with a large systemic acute dose of rIL-12.  It is generally agreed that low 
constitutive IL-12 expression kinetics are produced by IL-12 EGT and one of the advantages of 
EGT is local expression without significant, potentially toxic systemic levels of cytokine.  To 
determine whether clinical application of the optimized EP parameters with ttIL-12 yielded the 
safe expression kinetics, we determined plasma cytokine levels in all of the sacrificed mice. The 
previously determined parameters yielded efficient transfection of the gene for ttIL-12 in vivo 
using the Medpulser™ as indicated by detection of significant plasma cytokine levels only in IL-
12 DNA-treated mice (Fig. 8B & 8C), yet we found no statistically significant elevation in 
systemic plasma cytokine levels.  Mean levels of IL-12 p70 protein peaked at about 600 pg/mL 
in the 5 µg dose group on day three, and at approximately 60 µg/mL in the 1 µg therapeutic dose 
group on day seven.  Levels of IFNγ also increased after treatment, with the mean peak value 
reaching approximately 120 pg/mL on day seven in the 5 µg treatment group, and approximately 
360 pg/mL in the 1 µg treatment group.   
Thus, EP parameters using the Medpulser™ electroporator and four-needle electrode 
array were effective in numerous reporter genes and for therapeutic ttIL-12.  As expected, 
systemic levels of IL-12 were not significant enough to potentially cause systemic toxicity.  
Additionally, levels of IL-12 were greater in the higher dose group – particularly on day three.  
The results for IFNγ were similar, but higher levels were seen in the low dose IL-12 group 
compared to the high dose group at acute time points.  It is possible that IFNγ production was 
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pyogranulomatous to granulomatous myositis followed by myoregeneration and resolution were 
seen at site of needle electrode insertion in numerous mice in all of the groups that received IM 
EP (Fig. 9).  The incidence of detectable muscle damage peaked at seven days for the ttIL-12 
treated mice, and was maximal on day 1 for the 0.45% saline treated mice.  These trends may 
reflect the more widespread tissue inflammation over time and chances of detecting a change, 
more than reflecting increasing severity; in fact, by day 30, no muscle lesions were detected 
except for a single small focus of muscle degeneration, myofiber loss, and mineralization in a 
mouse of the 5 µg ttIL-12 treatment group (in a mouse that also had marked dystrophic cardiac 
calcification (DCC)).  
We also monitored behavior and performed periodic physical examinations of the mice 
after EP and found that several mice were transiently lame in one or both pelvic limbs after IM 
EP.  Mice that were lame were rechecked periodically and clinically detectable lameness 
resolved completely in all mice by seven days after IM EP.  There was not relationship between 
the incidence or severity of lameness and the substance injected. 
Liver Toxicity from ttIL-12.  The biggest concern regarding adverse effects from IL-12 
was hepatotoxicity; therefore several lobes of liver were examined histologically for ttIL-12 EGT 
lesions and a scoring system was used to document severity and incidence of lesions in different 
treatment groups (Fig. 10). There was a mild increase in the detection of liver lesions over time 
in the two ttIL-12 treatment groups, but none seen in either the control mice or the 0.45% saline 
treated mice (Fig. 10).  Although none of the toxicity appeared serious, the most severe lesions, 
and the highest incidence of lesions, were seen on day seven (Fig. 10).  Lesion incidence and 
severity were also greater in the 5 µg ttIL-12 treatment group than in the 1 µg ttIL-12 treatment 
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Systemic Immune Effects of ttIL-12 EGT.  In order to determine if there were any significant 
systemic effects of ttIL-12 EGT on the hematopoietic system and systemic immunity, CBCs and 
bone marrow histology were evaluated. In the case of WBC,  there was a trend to decreasing 
total counts up to day seven which returned to normal by day 30 (Fig. 11).  The trend was not 
significantly different from control mice in the 1 µg treatment group (p = 0.053 on day 3 and p = 
0.109 on day 7), but was in the 5 µg treatment group (p = 0.017 on day three and p = 0.023 on 
day seven).  The incidence of infectious disease was essentially non-existent (except possibly for 
mild BALT hyperplasia) in all groups except for the 5 µg ttIL-12 treatment group, which had 
two mice on day 30 that had severe, potentially life-threatening, infectious diseases.  One mouse 
had a moderate to severe, multifocal to coalescing, pyogranulomatous cholangiohepatitis (Fig. 
11B), and the other mouse had severe, bilateral, subacute to chronic, diffuse, pyogranulomatous 
pyelonephritis (Fig.11C).  Of note is the fact that the second mouse also was one of the mice 
with DCC.  No effects on bone marrow or other hematopoietic parameters were noted. 
Dystrophic Cardiac Calcification.  In histologically evaluating all other organs for 
potential ttIL-12 EGT toxicity, the only other major change seen in any of the mice was seen in 
the day 30, 5 µg ttIL-12 treatment group, which had 3 mice (25%) with moderate to severe DCC 
(Fig. 12).  Of these mice, one died, and one had evidence of biventricular congestive heart failure 
(pulmonary edema with splenic and hepatic congestion) at the time of sacrifice.   
As noted above, the only fatality in the 192 mice of this study was a female in the mega-
dose 5µg chronic 30 day group that died on day 22 after the IM EGT treatment.  The cause of 
death in this mouse was thought to be biventricular congestive heart failure secondary to DCC.  
Aside from severe myocardial mineralization (similar to Fig. 5B, but more severe), this mouse 
had hepatosplenomegaly due to congestion and mild hemosiderosis in the liver, spleen, and 
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Several clinical trials are beginning or underway in humans using EP to deliver DNA in 
the form of vaccines or therapeutic genes; however, only one toxicology study was found in the 
literature  using tumor-bearing mice to examine the safety of IL-12 gene EGT 156.  Furthermore, 
the aforementioned study used high voltage (1,300 V/cm), short duration (0.1 msec) EP pulses in 
contrast to the low voltage (200 V/cm), and long-duration (60 msec) pulses used in the current 
study.  The electrode array used was also different than the one used in this study (a six-needle 
array versus the current four-needle array). 
Comparing the different EP parameters, we did find effective transfection using the 
current parameters (Fig. 8), but it was important to also determine if these EP parameters caused 
any serious adverse effects.  In addition to establishing the safety of the current set of EP 
parameters, it was also important to establish the safety of ttIL-12.  Theoretically, a tumor-
targeted gene should be both safer and more efficacious than a systemically-administered, non-
targeted gene.  As expected, therapeutic use of ttIL-12 EGT was found to be safe and well 
tolerated under conditions likely to be used for EGT clinically (Figs. 9, 10, & 11).   
To our knowledge, this is also the first large scale study of IL-12 toxicity in non-tumor 
bearing mice, and the first examining the effects of relatively low voltage, long duration EP 
pulses.  Tumor-bearing mice are not normal immunologically161-163, so extrapolation from 
studies in tumor-bearing mice is fraught with a number of variables which may affect toxicity 
and efficacy of immune therapy.   Additionally, both transfection efficiencies and local EP 
effects vary widely depending on the EP system used. 
Using these parameters, local muscle changes in response to EP were completely 
resolved by day 30.  Interestingly, damage was more frequently detected on days one and three 
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in the group treated with carrier only – perhaps because of the hypotonic osmolarity of the half-
strength saline compared to DNA solutions.  A protective effect of ttIL-12, other than adding 
colloidal pressure, seems unlikely at these acute time points but cannot be ruled out.  Although 
the damage was detectable, albeit transient, these changes should be viewed with the perspective 
that inserting the 4 mm wide, four electrode array into mouse quadriceps affected a much greater 
muscle mass than would be commonly used in humans – perhaps this would be analogous to 
penetrating human thighs with four equidistant railroad spikes spaced 25-50 cm apart and 
applying an electric field.  In addition to the histologic muscle changes seen after EP, several 
mice were transiently lame in the pelvic limbs the day after EP, but subsequently returned to a 
normal gait and stance thereafter. 
We chose C3H/HeJ  mice in this study based on previously documented  gross toxicity 
164 and our previous experience suggesting that they were more sensitive to IL-12 liver toxicity 
than other commonly used strains of inbred mice.  Concerns about the well documented (16) 
defective TLR4 signaling in C3H/HeJ mice were not thought to be an issue because TLR4 
signaling in mice appears to serve primarily as a lipopolysaccharide (LPS) response pathway.  
Thus, C3H/HeJ  mice are immunologically normal, except for their inability to respond to LPS 
and to counter Gram negative infection 165.  Liver and immune changes were detected in this 
study, but are not thought to be strain-specific.  
Liver changes have been described before with rIL-12 therapy 164.  Similar to our 
findings, mice in previous rIL-12 studies had foci of hepatocellular necrosis with aggregates of 
Kupffer cell hyperplasia.  In this study we have also noted occasional neutrophil and 
lymphocytes interspersed within the aggregates of Kupffer cells in the acute treatment groups.  
Lesions in the mice in this study were mild to minimal and transient.  The number of lesions 
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correlated with minimal elevations in ALT, but we found no increase in alkaline phosphatase 
(ALP) and no decrease in albumin (ALB) as was previously seen in rIL-12 toxicity 164.  We 
chose not to determine levels of aspartate transaminase (AST) because this enzyme is also 
elevated in cases of muscle damage and is therefore not liver-specific.  If liver toxicity were a 
concern, our results suggest that monitoring serum levels of ALT during therapy would be 
indicated.  
Immune suppression and suppressed leukocyte counts have also been described with IL-
12 therapy 164.  In our study, both total white cell counts and individual absolute leukocyte counts 
were decreased after treatment with ttIL-12.  Mean absolute leukocyte counts for neutrophils, 
lymphocytes, monocytes, and eosinophils never decreased significantly from control mice.  
Mean total WBC did decrease significantly (p<0.05) from control levels on days three and seven 
in mice treated with 5 µg of ttIL-12.   Furthermore, in the 5 µg ttIL-12 group there were two 
mice that developed major infectious diseases; one mouse also had concurrent severe DCC 
which may have been a significant stressor predisposing the mouse to pyelonephritis (or 
pyelonephritis may have predisposed to DCC); the other mouse had moderate to severe 
cholangiohepatitis.  Since no other mice in the study developed serious infectious disease, there 
is a possibility that mega-dose ttIL-12 may cause clinically relevant immune suppression.  
Conversely, at therapeutically relevant doses (1 µg), ttIL-12 EGT is unlikely to cause serious 
immunosuppression.  Nevertheless, in addition to monitoring ALT, we suggest monitoring WBC 
during therapy – especially if combined with immunosuppressive chemotherapeutics.   
DCC was the most serious problem potentially linked to ttIL-12 EGT.  Although both of 
the females with clinical signs attributed to DCC (death and congestive heart failure) were well 
within the reported 81-89 day range for development of DCC in female C3H/HeJ mice 166, DCC 
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seen in the 100-day-old male mouse (which did not have signs of CHF)  was well before the 
normal onset of 292-465 days reported previously 166.  No other mice in the study developed 
detectable DCC suggesting that this 16% premature incidence in the mega-dose male mice may 
not have been significant.  Nevertheless, until additional studies are done in mice that are not 
predisposed to DCC, mega-doses of ttIL-12 would be contraindicated in subjects with similar 
genetic predisposition. 
DCC is common in many strains of imbred mice 167.  In C3H mice, DCC is caused by a 
mutation in the ABCC6 gene leading to deficiency of its protein product, MRP6 168.  MRP6 is 
expressed primarily in the liver and kidney but also exists in many other tissues throughout the 
body, and is in the family of ABC transporters.  It has long been known that DCC can be 
triggered in susceptible mice by a variety of stimuli including:  female sex – particularly in 
breeders, high fat diets, infectious agents 169, 170, hormonal status 166, 171, 172, diet 166, and freeze-
thaw injury (20).  In this study, we found that ttIL-12 EGT also appears to hasten the onset of 
DCC in C3H/HeJ mice. 
In summary, we can conclude that ttIL-12 EGT using low-voltage, long-duration pulses 
is safe and well-tolerated at therapeutically relevant dosages.  Mild muscle changes seen after IM 
EP are unlikely to be a problem in humans given the small area electroporated.  Transient acute 
decreases in total WBC may suggest possible mild immune suppression, so vigilant patient 
monitoring for infectious disease and serial CBCs would be prudent. However, no infectious 
diseases were seen in study mice at the clinically relevant dose of 1 µg ttIL-12.  Likewise, DCC 
was not a problem in the 1 µg therapeutic dosage group. However, several mice (three of twelve, 
or 25%) were affected in the mega dose (5 µg) group at day 30, one of which presumably died of 
congestive heart failure secondary to DCC.  Thus, until additional information is available, 
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people with ABCC6 gene defects or patients with Pseudoxanthoma elasticum (a heritable 
disorder of the connective tissue, caused by defective ABCC6 gene) should be excluded from 
treatment with mega-dose ttIL-12 EGT.  Finally, no effect of ttIL-12 EGT on wound healing was 
seen – even at a dosage twenty times greater than those likely to be used clinically.  Thus, given 
the safety of this treatment modality, and superiority to wild-type IL-12 therapy (Cutrera, 
submitted manuscript) we strongly recommend proceeding to phase I trials. 
ADDITIONAL OBSERVATIONS 
 In addition to the data published herein, Appendix 1 includes data demonstrating that 
there was no difference in weight gain between groups, and the incidence of lameness following 
IM electroporation (consistently higher in the 0.45% saline control group). 
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Cancer continues to remain a major cause of morbidity and mortality throughout the 
world.  Conventional surgery, chemotherapy, and radiation therapy have failed to result in a 
significant impact on the rates of death from cancer; therefore, there is a real need for better 
therapies.   Immune therapy in general and cytokine gene therapy specifically, offers several 
advantages over conventional treatment modalities.  In addition to being able to effectively target 
tumor metastases and recurring primary tumors, we have found that cancer electroimmunogene 
therapy is cost effective, safe, and easy to perform.  
If treatment in humans shows as much promise as seen in our pre-clinical trials, and is as 
safe as seen in the studies described herein, this therapeutic may offer a significant impact in the 
war against cancer.  As summarized in this dissertation, there have been significant advances in 
the use of electroporation resulting in several clinically-approved electroporators.  We have 
already proved utility of this technique when combined with electrochemotherapy in treating 
locally aggressive oral tumors in dogs in addition to our extensive previous data in mice.  
Perhaps most importantly in terms of being able to advance to human clinical trials, we have 







































Mean Body Weights for Each Group:  There was no significant difference in body weights 
between treatment groups.  (Mean +/- Standard Deviation in grams) 
GROUP*  Day 0  Day 1  Day 7  Day 10**  Day 11  Day 19  Day 26  Day 33  Day 40 
CONTROL1  25+/‐3.1  25.2+/‐2.9  25.1+/‐3.2  25.1+/‐3.1  25.4+/‐3.2         
SALINE1  24.9+/‐2.1  25.1+/‐2.2  25.2+/‐2.5  25.1+/‐2.8  25.4+/‐3         
1 µg1  25.2+/‐3.1  25.3+/‐3  25.2+/‐3  25.4+/‐3.1  25.3+/‐3.1         
5 µg1  24.2+/‐2.3  24.3+/‐2.3  24.6+/‐2.3  25.3+/‐2.6  25.2+/‐2.4         
CONTROL3  23.9+/‐2.9  24+/‐2.5  24.3+/‐2.5  25.2+/‐2.6  24.6+/‐2.1  24.4+/‐2.6       
SALINE3  24.4+/‐3.6  24.8+/‐3.6  24.8+/‐3.5  25.4+/‐3.6  25.3+/‐3.6  25.4+/‐3.6       
1 µg3  25+/‐3.4  25.6+/‐3.3  25.6+/‐3.3  25.8+/‐3.5  25.7+/‐3.5  25.6+/‐3.8       
5 µg3  25+/‐2.9  25.3+/‐3.1  25.4+/‐3.3  25.8+/‐3  25.7+/‐3.4  26+/‐3.3       
CONTROL7  23.5+/‐3  23.9+/‐3.1  24.1+/‐2.9  24.4+/‐2.8  24.9+/‐2.8  24.7+/‐3  24.7+/‐3     
SALINE7  23.4+/‐1.9  24.3+/‐2.1  24.7+/‐2.1  24.8+/‐2  25.1+/‐2.2  25.6+/‐2.7  25.6+/‐2.7     
1 µg7  22.9+/‐2.7  23.6+/‐2.6  24+/‐2.6  24.4+/‐2.7  24.5+/‐2.9  25+/‐3  25+/‐3     
5 µg7  23.1+/‐2.3  23.8+/‐2.3  24.1+/‐2.5  24.2+/‐2.3  24.9+/‐2.3  25.7+/‐2.2  25.7+/‐2.1     
CONTROL30  22.8+/‐2.2  23.7+/‐2.1  23.6+/‐1.9  22.3+/‐1.9  24+/‐2.1  24.6+/‐2.1  25.5+/‐2  26.2+/‐1.8  27+/‐2 
SALINE30  23.1+/‐2.1  23.9+/‐2.1  23.8+/‐1.9  23.3+/‐2.3  24.5+/‐2  25.3+/‐2  26.3+/‐1.9  26.7+/‐1.7  27.4+/‐1.7 
1 µg30  23.8+/‐3.1  24.1+/‐2.8  23.6+/‐3.2  23+/‐3.7  23.9+/‐3.5  24.4+/‐3.3  24.7+/‐3  25.1+/‐3  25.4+/‐2.9 
5 µg30  23.9+/‐2.7  24.4+/‐2.7  23.7+/‐3.4  23.3+/‐3.9  24.2+/‐3.4  24.6+/‐3  24.8+/‐2.7  25.3+/‐2.5  25.9+/‐2.1 
 
*The Subscript following the group identity is number of days between treatment and euthanasia. 












Percentage of mice with detectable lameness after electroporation:  All groups had some 
members with detectable lameness.  The only consistent trend was a greater incidence of 
lameness in the saline control group. 
GROUP*  Day 0  Day 1  Day 7  Day 10**  Day 11  Day 19  Day 26  Day 33  Day 40 
CONTROL1  0  0  0  0  42         
SALINE1  0  0  0  0  58         
1 µg1  0  0  0  0  25         
5 µg1  0  0  0  0  33         
CONTROL3  0  0  0  0  33  0       
SALINE3  0  0  0  0  50  0       
1 µg3  0  0  0  0  17  0       
5 µg3  0  0  0  0  17  0       
CONTROL7  0  0  0  0  17  0  0     
SALINE7  0  0  0  0  42  0  0     
1 µg7  0  0  0  0  8  0  0     
5 µg7  0  0  0  0  25  0  0     
CONTROL30  0  0  0  0  25  0  0  0  0 
SALINE30  0  0  8  0  50  8  0  0  0 
1 µg30  0  0  0  0  17  0  0  0  0 
5 µg30  0  0  0  0  17  8  0  0  0 
 
*The Subscript following the group identity is number of days between treatment and euthanasia. 
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